Abstract Body

Background: Our previous studies using sensitive testing to better assess transmitted HIV drug resistance were limited to a few large urban areas. Here we applied sensitive resistance screening on a population drawn from broader geographic regions and population densities in the United States.

Methodology: We used validated allele-specific PCR assays to screen 1070 de-identified plasma specimens collected in 2009-2011 within 3 months of HIV diagnosis from persons with no reported evidence of antiretroviral drug use. We focused on five RT mutations as sentinel markers of transmitted drug resistance, comprised of the historically frequently transmitted mutations, M41L, K103N, Y181C, and M184V, and a rare but clinically important mutation, K65R. The screening assays are capable of detecting resistant minority variants above random quasispecies noise at levels 10-100-times below what conventional bulk genotyping can detect. We determined the prevalence of transmitted resistance by demographic characteristics and used chi-square tests to compare percentages.

Results: Transmission prevalence of the five mutations with sensitive testing (16.6%) was 2.1-times that detected by conventional sequencing (7.9%) (p<0.0001). The increase was least for K103N (7.0% to 8.4%, 1.2-times), and greatest for K65R (0% to 1.7%). One-third of the K65R mutations were in samples with ≥1 of the other four mutations screened. The study population was 54% black, 29% white, 71% men who have sex with men (MSM), 14% female, and the major age group was 20-29 years (40%). By race/ethnicity, the prevalence of transmitted resistance by sensitive screening for whites (16.4%) and blacks (14.9%) were both significantly higher than for Hispanics/Latinos (6.4%) (p=0.005 and 0.013, respectively). By age, resistance prevalence was highest (23.1%) in those 13-19 years (85% were black) followed by 50-59 years (17.7%). Additionally, the 14.3% drug resistance prevalence identified in women (72% were black) was nearly the 15.1% prevalence observed for MSM (47% were black). Transmitted resistance prevalence in population densities of <50,000, 50,000-499,999, and ≥500,000 was 16.4%, 16.3%, and 13%, respectively (P=0.13).

Conclusions: The majority of transmitted resistance in this population was not detected by conventional testing. HIV transmission involving resistant virus was similar across genders and population densities. A substantial drug resistance burden was identified in the <20 year olds, who were predominantly black. The findings highlight the importance of sensitive testing for accurate drug resistance screening and underscore the importance of prevention efforts for at-risk youth.